Anti-MRC1 Antibody, clone 1C9 ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 1C9 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Macrophage mannose receptor 1 (MRC1). It targets an epitope within 25 amino acids from the C-terminal region.
• Immunogen: KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal region of human Macrophage mannose receptor 1 (MRC1).
• Application: Anti-MRC1, clone 1C9 ZooMAb, Cat. No. ZRB1440, is a recombinant Rabbit monoclonal antibody that specifically targets MRC1 and is tested in Affinity Binding Assay, Flow Cytometry, Immunocytochemistry, Immunohistochemistry, and Western Blotting.
• Target description: Macrophage mannose receptor 1 (UniProt: P22897; also known as MMR, C-type lectin domain family 13 member D, C-type lectin domain family 13 member D-like, Human mannose receptor, hMR, Macrophage mannose receptor 1-like protein 1, CD206, MRC1) is encoded by the MRC1 (also known as CLEC13D, CLEC13DL, MRC1L1) gene (Gene ID: 4360) in human. MRC1 is a single-pass type I membrane protein that mediates the endocytosis of glycoproteins by macrophages. It also functions in phagocytosis and plays a role in immune homeostasis by scavenging unwanted mannoglycoproteins. It is expressed on the surface of macrophages, immature dendritic cells and liver sinusoidal endothelial cells. It is a C-type lectin with eight C-type lectin domains and can bind both sulfated and non-sulfated polysaccharide chains. MRC1 is synthesized with a signal peptide (aa 1-18), which is subsequently cleaved off to generate the mature form that contains a large extracellular domain (aa 19-1389), a transmembrane domain (aa 1390-13410), and a cytoplasmic tail (aa 1411-1456). The extracellular region includes an N-terminal cysteine-rich domain that binds glycoproteins bearing sulfated sugars that terminate in 4-SO4GalNAc, a fibronectin II (FNII) domain, and eight carbohydrate recognition domains that bind sugars like mannose and fucose with high affinity. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in lyophilized from PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.
• Reconstitution: 0.03 mg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.